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ABSTRACT
Background. Osteoprotegerin (OPG) is used for the systemic treatment of bone
diseases, although it has many side effects. The aim of this study was to investigate a
newly formulated OPG-chitosan gel for local application to repair bone defects. Recent
studies have reported that immunodetection of osteopontin (OPN) and osteocalcin
(OC) can be used to characterise osteogenesis and new bone formation.
Methods. The osteogenic potential of the OPG-chitosan gel was evaluated in rabbits.
Critical-sized defects were created in the calvarial bone, which were either left unfilled
(control; group I), or filled with chitosan gel (group II) or OPG-chitosan gel (group
III), with rabbits sacrificed at 6 and 12 weeks. Bone samples from the surgical area were
decalcified and treated with routine histological and immunohistochemical protocols
using OC, OPN, and cathepsin K (osteoclast marker) antibodies. The toxicity of the
OPG-chitosan gel was evaluated by biochemical assays (liver and kidney function tests).
Results. The mean bone growth in defects filled with the OPG-chitosan gel was
significantly higher than those filled with the chitosan gel or the unfilled group (p<
0.05). At 6 and 12 weeks, the highest levels of OC and OPN markers were found in the
OPG-chitosan gel group, followed by the chitosan gel group. The number of osteoclasts
in the OPG-chitosan gel group was lower than the other groups. The results of the liver
and kidney functional tests indicated no signs of harmful systemic effects of treatment.
In conclusion, the OPG-chitosan gel has many characteristics that make it suitable for
bone repair and regeneration, highlighting its potential benefits for tissue engineering
applications.
Subjects Bioengineering, Orthopedics, Pharmacology
Keywords Osteocalcin, Osteopontin, Cathepsin K, OPG-chitosan gel, Rabbit
INTRODUCTION
The gold standard for bone regeneration is an autologous bone graft. However, the
procurement of autogenous bone comes with some disadvantages, such as creating
an additional surgical area, significant morbidity, and limited source material. Thus,
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bone tissue engineering and regenerative medicine can be employed to improve bone
regeneration (Arrigoni et al., 2013; Muschler et al., 2010; Sasso et al., 1998). The discovery
of osteoprotegerin (OPG) as an inhibitor of osteoclast activity and maturation has led
to new research exploring the applicability of OPG as a potential therapeutic agent for
the treatment of bone diseases and to induce bone formation (Bekker et al., 2001; Fili,
Karalaki & Schaller, 2009; Hofbauer et al., 2001; Kostenuik et al., 2001). The first clinical
trial evaluated the efficacy of recombinant Fc-OPG, used systemically as a drug for the
treatment of osteoporosis in postmenopausal women (Bekker et al., 2001) and another
study evaluated a different formulation of OPG, known as AMGN-0007, in patients with
lytic bone lesions associated with multiple myeloma or breast carcinoma (Body et al.,
2003). Both of these studies reported that Fc-OPG treatment resulted in reduced bone
turnover markers when administered at a low dose, and had a longer antiresorptive effect
when administered at an equivalent dose. The authors of these studies cited two potential
concerns with Fc-OPG therapy. The first is the generation of anti-Fc-OPG antibodies,
which might cross-react with endogenous Fc-OPG, neutralising its activity. The second
potential concern is the binding of Fc-OPG to TNF-related apoptosis-inducing ligands,
which could inhibit their role in tumour surveillance (Schwarz & Ritchlin, 2007). These side
effects are, in part, due to systemic administration of the treatment. Recently, it was reported
that twice-weekly injections with a high dose of OPG-Fc (5.0 mg/kg) into the mesial and
distal mucosa of the first molars during orthodontic movement improved bone quantity
and orthodontic anchorage in a rat model (Fernández-González et al., 2016). In addition,
OPG-chitosan matrices have been shown to enhance cell growth and proliferation, as well
as increasing the production of osteopontin (OPN) and osteocalcin (OC) protein levels
(Jayash et al., 2016). In order to optimise the OPG concentration and prolong the duration
of protein release, aimed at avoiding the side effects associated with systemic application, a
controlled drug delivery system for the local application of OPG is required. Chitosan was
selected as the matrix material for this method of drug delivery.
Bonematrix proteins such asOPN function to induce osteoclastmigration and adhesion,
while OC functions to regulate mineralisation. These functions highlight the importance of
measuring bone matrix proteins when characterising osteogenesis processes, as well as the
influence of the drug on their expression (Bondarenko et al., 2014). Cathepsin K is one of
the biomarkers expressed by osteoclasts during active bone resorption, making it a useful
and specific biomarker of osteoclastic activity. Cathepsin K is expressed by osteoclasts and
a small number of osteoclast precursors, but it is not expressed by osteoblasts or osteocytes.
Therefore, its expression is specific to the resorption phase of bone metabolism (Drake et
al., 1996).
We previously formulated and investigated anOPG-chitosan gel for its cytocompatibility
(Jayash et al., 2017a); however, the in vivo effects on bone regeneration were not extensively
investigated and discussed in our previous work. In the present paper, we investigated
the efficacy of an OPG-chitosan gel in bone regeneration in terms of the expression of
osteoblast- and osteoclast-specific proteins, and tested the toxicity of the OPG-chitosan gel
by biochemical assays (liver and kidney function tests).
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METHODS
Formulation of the osteoprotegerin-chitosan gel
The OPG-chitosan and chitosan gels were prepared using water-soluble chitosan (25 kDa).
Recombinant human OPG protein (1 mg/mL) was used to prepare the OPG-chitosan gel
(PeproTech, Rocky Hill, NJ, USA) with a chitosan binder (85 kDa). The methodology for
preparing the OPG-chitosan gel has been described previously (Jayash et al., 2017b) and
patented under the title, ‘‘An osteoprotegerin-chitosan gel for bone tissue regeneration’’
(PI 2016701598,UM).
Animal model
The animal experiment was authorised by the Institutional Animal Care and Use
Committee at the University of Malaya (FOM IACUC), and registered under number
20150115/DENT/R/NAB. Critical-sized defects were created in the calvarial bone of 18
New Zealand white female rabbits (6 months old; 3.5–4 kg). The rabbits were divided
into three groups: (i) untreated control group (group I; n= 6), (ii) chitosan-only gel
(group II; n= 6), and (iii) OPG–chitosan gel (group III; n= 6). The anaesthesia, surgery,
medical treatment, and euthanasia procedures have been described previously (Jayash et
al., 2017a). Three rabbits from each group were examined at 6 and 12 weeks. The bone
samples were fixed in 10% neutral buffered formalin for 24 h, decalcified in 10% EDTA
for 3 weeks, then embedded in paraffin according to the established technique. Three
4-µm thick sections from each paraffin block were cut using a microtome (Leica, Wetzlar,
Germany). For histological studies, the sections were stained with haematoxylin and eosin
(H&E). Immunohistochemistry was performed according to established methods (Gruber
& Ingram, 2003; Bondarenko et al., 2014). The anti-OPN (clone 1B20; Novus Biologicals,
Cambridge, UK), anti-OC (OCG3; Abcam, Cambridge, UK), and cathepsin K (Biovision,
Milpitas, CA, USA) polyclonal antibodies have previously been verified in rabbit bone
tissue (Arrigoni et al., 2013; Bondarenko et al., 2014).
Quality control
A negative control reagent was used with each specimen to identify any non-specific
staining. If non-specific staining could not be clearly differentiated from specific staining,
the labelling of the test specimen was considered invalid. In this experiment, rabbit
immunoglobulin fraction (normal; Dako, Industrial RowTroy, Michigan, USA) was used
as the negative control.
Histological evaluation
Verification of the immunohistochemical reaction was performed using a light microscope
and scanned using a digital slide scanner (3DHISTECH Ltd., Budapest, Hungary). The
results were assessed using computer-assisted image analysis (ImageJ; National Institutes of
Health, Bethesda, MD, USA). The image was opened and the image threshold was adjusted
until all stained areas were selected. A histogram was displayed to provide assistance.
Staining was assessed by setting a threshold using the threshold tool. The threshold tool
settings that successfully quantified the staining in a positive-stained specimen were
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repeated in every image for comparison. The analysed–set measurement was selected,
and the parameters to be measured were chosen (Jensen, 2013). The mean and standard
deviation were calculated for each sample.
Serum biochemical parameters
Blood samples were collected from all rabbits before surgery and before sacrifice. The blood
samples were allowed to clot at room temperature before centrifuging at 1,000 g for 10 min.
The serum was separated and analysed for markers of kidney function, including creatinine
and urea nitrogen, and markers of liver function, including alkaline phosphatase (ALP)
and alanine aminotransferase (ALT). Analyses were conducted using a clinical chemistry
analyser (902; Hitachi, Tokyo, Japan) with standard diagnostic kits (Hitachi 902, Roche).
Statistical analysis
Statistical analyses were performed using the parametric one-way ANOVA test and non-
parametric Mann–Whitney U and Kruskal–Wallis tests for comparison between the mean
values of different groups. The significance value was set at p< 0.05. Results are presented
as the mean (arithmetic mean) and standard deviation.
RESULTS
Clinical findings
At 6 weeks, rabbits in group III (OPG-chitosan gel) showed partially healed surgical defects,
which were filled with a dense, opaque structure (bone). On the other hand, the surgical
defects of groups I (surgery only) and II (chitosan gel) were completely filled with thin,
transparent soft tissue. At 12 weeks, the surgical defects of groups II and III were completely
filled with hard tissue, whereas the defects of group I were still only partially healed, with
regions of soft tissue (Fig. 1).
Histological results (haematoxylin and eosin staining)
At 6 weeks, the defects of rabbits in group III were filled with new bone and osteoid tissue,
while the group II defects were filled with new bone and fatty marrow. However, the group
I defect was only partially filled, with the least amount of new bone compared to groups II
and III. The connective tissue of the bone bridge in groups II and III was less prominent
than that of group I. No graft particles were seen at 6 weeks, which suggests that the particles
may have been completely resorbed. The new osteoid bone filling each of the defects was
formed within the region of interest. The trabecular bone in group II appeared thick and
dense, while the trabecular bone in group III had become lamellar bone.
At 12 weeks, newly formed bone had completely filled the defect of rabbits in group
III. The newly formed bone in these defects resembled a bridge, and was arranged as
lamellae in some areas. These areas contained large osteons and Haversian canals, as well
as highly cellularised connective tissue, especially within the central region. Moreover,
cortical organisation was evidenced by the presence of trabecular projections, in addition
to the maturation of lamellar bone indicated by thickening at the margin of the defect
compatible with the original bone structure of the region (Fig. 2).
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Figure 1 Gross appearance of surgical defects at 6 and 12 weeks. (A) Group I (control), (B) group II
(chitosan gel), and (C) group III (OPG-chitosan gel).
Immunohistochemistry results
Osteoblast markers
At 6 weeks, OPN immunolabelling was observed in the osteoclasts, osteoblasts, and
fibroblasts. In almost all specimens, OPN immunoreactivity was located within the matrix
of compact bone, cancellous bone, and osteoid. Osteocalcin immunoreactivity appeared
in the matrix of compact bone, but was weaker in cancellous bone and osteoid (Fig. 3).
At 12 weeks, OPN expression was characterised by osteoid staining in all investigated
groups. Immunolabelling of OPN was observed in osteoblasts. The bone matrix also
showed stained areas. Osteocalcin was detected in the matrix of compact bone, but showed
reduced expression in osteoid and bone cells (Fig. 4).
Based on the parametric one-way ANOVA, there was a significant difference in the
mean percentage of OPN expression between groups I and III (p< 0.05). The highest
expression of OPN was observed in group III, followed by group II and group I, which
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Figure 2 Photomicrographs of defect sites of (A) Group I, (B) Group II (C) Group III at 6 and 12
weeks. Sections were stained with haematoxylin and eosin. NB, new bone; OS, osteoid; FM, fatty marrow;
HC, Haversian canal; TB, trabecular bone. (Scale bar represents 500 µm.)
showed the lowest OPN expression. Based on the parametric one-way ANOVA, there was
no significant difference in the mean percentage of OPN expression between groups II and
I (p> 0.05). However, there was a significant difference in the mean percentage of OPN
expression between groups III and II (p< 0.05; Fig. 5).
Statistical analysis of the percentage of OC expression at 6 weeks showed a significant
difference between groups I, II and III (p< 0.05). The highest OC expression was found in
group III, followed by group II (Fig. 5). Regarding OC expression at 12 weeks, there was a
significant difference in themean percentage of OC expression in group III when compared
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Figure 3 Photomicrographs of immunostaining for osteocalcin and osteopontin in (A) Group I, (B)
Group II (C) Group III at 6 weeks. The pictures are arranged by staining technique (columns) and the in-
vestigated treatment (rows). Areas that stained positive for osteocalcin and osteopontin are indicated by
red arrowheads. NB, new bone; OS, osteoid; FM, fatty marrow.
to groups II and I (p< 0.05). There was also a significant difference in the mean percentage
of OC expression between groups III and I (p< 0.05). The highest OC expression at 12
weeks was found in group III, followed by group II (Fig. 6).
In the intragroup comparison, there was a significant difference in OPN expression
between 6 and 12 weeks in all groups (p< 0.05), with the highest expression of OPN
observed at 6 weeks. Similarly, there was a significant difference in OC expression between
6 and 12 weeks in all groups, with the highest expression observed at 6 weeks.
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Figure 4 Immunohistological results at 12 weeks for (A) Group I, (B) Group II (C) Group III. The pic-
tures are arranged by staining technique (columns) and by the investigated treatment (rows). Areas that
stained positive for osteocalcin and osteopontin are indicated by red arrowheads. NB, new bone; OS, os-
teoid; FM, fatty marrow; CB, compact bone; CAB, cancellous bone.
The expression of OPN andOC between 6 and 12weeks was compared for all groups.We
found no significant difference in the expression of OPN and OC in group III (p> 0.05).
In group II, however, there was a significant difference in the expression of OPG and OC at
6 weeks (p< 0.05), when OC was more highly expressed. In group I, there was a significant
difference between the expression of OPN and OC at 12 weeks, with higher expression
observed for OPN. As the sample size was small, non-parametric tests were also carried
out, and similar results were obtained.
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Figure 5 Statistical analysis of the percentage expression of osteopontin as a bone-formationmarker
between groups I, II and III at 6 and 12 weeks.Data are presented as the average of three independent ex-
periments (n= 3). ∗∗Significant difference between the control (group I) and experimental groups (groups
II and III). ∗Significant difference between groups III and II. A p-value of <0.05 was considered significant
in all analyses.
Osteoclast marker
More cathepsin K-positive areas were observed in the medullary region of the defect site
than the cortical bone region at both 6 and 12 weeks. Cathepsin K-positive multinuclear
cells were also detected within the newly-formed bone. In addition, fewer osteoclasts were
detected at 12 weeks than at 6 weeks for all groups (Fig. 7).
Serum biochemical parameters
The serum biochemistry results of rabbits in groups I, II and III at baseline and at 6 and 12
weeks are summarised in Tables 1 and 2. There were no significant changes in the levels of
creatinine and urea nitrogen. In addition, no significant differences in serum electrolytes
including calcium, potassium, and chloride were noted. The effects of OPG and/or chitosan
on liver function parameters such as albumin, ALT, G-glutamyl transferase, ALP and total
bilirubin were also examined. Animals in groups I, II and III showed no difference in
hepatic markers. The effects of treatment on triglyceride, high-density lipoprotein (HDL)
cholesterol, and total cholesterol levels are shown in Table 2. Rabbits in all groups showed
no significant changes in triglyceride, HDL cholesterol, or total cholesterol levels after
treatment.
DISCUSSION
Allografts and autografts present several clinical problems that need to be addressed, such
as transmission of infection, unpredictable resorption, pain at the donor site, and limited
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Figure 6 Statistical analysis of the percentage expression of osteocalcin as a bone-formationmarker
between groups I, II and III at 6 and 12 weeks.Data are presented as the average of three independent ex-
periments (n= 3). ∗∗Significant differences (p< 0.05) between control (group I) and experimental groups
(groups II and III).
donor source. To eliminate these problems, it would be advantageous to develop a material
that can promote bone regeneration at the defect site. The intention of this study was to
investigate the local of application of OPG-chitosan gel in a critical-sized defect in the
parietal bone in a rabbit models. To investigate this, three treatments (OPG-chitosan gel,
chitosan gel, and untreated control groups) were tested at 6 and 12 weeks. The clinical
results of the current study showed that treatment of surgical defects with the OPG-
chitosan gel was not associated with any signs of inflammation or infection. This indicates
biocompatibility of the newly formulated OPG-chitosan gel. At 12 weeks, the surgical
defects of rabbits treated with the chitosan gel were filled with new bone, as observed
from the histological sections. However, the defects in this group were only partially filled,
indicating that chitosan enhances bone formation. This observation is in agreement with
previous studies that reported a higher amount of bone formed in defects treated with
chitosan compared to untreated controls (Ezoddini-Ardakani et al., 2012). In addition, the
amount of bone formed was reduced when compared to those defects treated with chitosan
combined with other active components (Bush et al., 2016; Oktay et al., 2010).
Our observation that the surgical defects treated with OPG-chitosan gel (group III)
were completely filled with new bone suggests that the OPG protein represents an active
component that could improve bone regeneration. We also observed a large number of
osteons in the bone tissue of the OPG-chitosan group at 6 and 12 weeks. This observation is
in agreementwith an earlier study (Allegrini et al., 2006), and supports the notion that active
bone formation is taking place during the healing process. In any bony defect, the most
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Figure 7 Cathepsin K immunostaining of osteoclasts in groups (A) Group I, (B) Group II (C) Group
III at 6 and 12 weeks after surgery. Cathepsin K-positive multinuclear cells are indicated by red arrow-
heads. MR, medullary region.
intensive cellular reactions occur during the first 6 weeks, when the bone defect is initially
healed with trabecular bone consisting of primitive woven bone. After 6 weeks, there is
a reduction in the number of cells in the area of the defect, as well as increased calcium
deposition, which is in agreement with a study by Gehrke (2013). Bone remodelling was
also active after 8 weeks of healing in the rabbit, with various degrees of bone maturation
in addition to uneven osseous formation (Jansen et al., 1991).
The compatibility and osteoconductivity potential of the OPG-chitosan gel was evident
from the presence of progressive newbone formation and remodelling in the surgical defects
at 6 and 12 weeks. A previous study reported an osteoinductive effect of treatments used
to enhance bone formation in rabbits through the increased expression of bone-formation
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Table 1 Serum biochemical data for rabbits treated with OPG-chitosan (group III) or chitosan (group II) gels and untreated control rabbits
(group I) at baseline and 6 weeks after treatment.
Parameter Baseline 6 weeks Normal range
Group III Group II Group I Group III Group II Group I
Sodium mmol/L 142± 0 142± 1 141± 1 143± 0 141± 1 141± 0.7 139–146
Potassium mmol/L 4± 0.1 5± 0.4 5± 0.7 3.8± 0.1 3.95± 0.1 5± 0.6 3–5
Chloride mmol/L 103± 0.7 102± 0 101.5± 0.2 100± 4.2 101± 1 99.5± 4 104–116
Urea nitrogen mmol/L 8± 0.42 7± 1.5 8± 0.2 6± 1.5 7± 0.07 9± 0.07 6.35–16
Creatinine µmol/L 77± 6 78± 2 77± 5 102± 15 77± 7 85± 4 60–140
Albumin (g/L) 41± 0.0 38± 1 41± 1 39± 4 40± 4 40± 1 20–40
Total Bilirubin (µmol/L) <2 <2 <2 <2 <2 <2 2–5
Alkaline Phosphate (U/L) 102± 6 111± 8 110± 4.9 50± 10 81± 3 69± 3 17–192
Alanine Aminotransferase (U/L) 30.5± 3 94.5± 2 36± 15 35± 0 53± 12.7 52.5± 3.1 38–86
G-Glutamyl Transferase (U/L) 5.5± 0.7 5.5± 0.9 2.5± 0.7 6± 1.5 6.5± 1.4 5± 1.4 6–22
Triglyceride (mmol/L) 0.5± 0.1 0.7± 0.1 0.65± 0.2 0.5± 0.1 0.7± 0.15 0.75± 0 –
Total Cholesterol (mmol/L) 1± 0.2 0.9± 0.1 1.1± 0 1.3± 0.3 0.85± 0.2 1.2± 0.1 –
HDL Cholesterol (mmol/L) 0.8± 0.2 0.61± 0.1 0.8± 0.2 0.2± 0.1 0.62± 0.1 0.8± 0.1 –
Notes.
Data are expressed as the mean± SD of three rabbits per group.
Table 2 Serum biochemical data for rabbits treated with OPG-chitosan (group III) or chitosan (group II) gels and untreated control rabbits
(group I) at baseline and 12 weeks after treatment.
Parameter Baseline 12 weeks Normal range
Group III Group II Group I Group III Group II Group I
Sodium mmol/L 142± 2 142± 1 143±2 142± 2.6 143± 1 143± 2 139.3–145.7
Potassium mmol/L 4± 1 4± 0.3 4± 0.4 4± 0.6 4± 0.4 4± 0.5 3–5
Chloride mmol/L 100± 0.5 101± 0.6 98± 3.5 102± 0.2 101± 2 104± 4 105–116
Urea nitrogen mmol/L 8± 1 8± 1 9± 0.4 8± 1 7± 1 8± 1 6–16
Creatinine µmol/L 85.7± 10 87± 1 89± 2 89± 10 83± 2 87± 1 60–140
Albumin (g/L) 43.3± 3 40.7± 1 42± 1 41± 2.9 40± 3 39± 3 20–41
Total Bilirubin (µmol/L) <2 <2 <2 <2 <2 <2 2–5
Alkaline Phosphate (U/L) 68.5± 12 44± 3 69.5± 8 58± 1 44± 9 48± 8 17–192
Alanine Aminotransferase (U/L) 58± 6.9 60± 9.7 48.7± 10 53.7± 15.8 67± 12 54± 7 38–86
G-Glutamyl Transferase (U/L) 6± 1.2 7± 1.5 3± 1.4 4± 0.6 7± 1.7 5± 1.2 6.00–22.00
Triglyceride (mmol/L) 0.7± 0.5 0.6± 0.2 0.4± 0.01 1.2± 0.2 0.6± 0.2 0.5± 0.2 –
Total Cholesterol (mmol/L) 1± 0.2 1± 0.2 1± 0.2 1± 0.2 1± 0.2 1± 0.2 –
HDL Cholesterol (mmol/L) 0.7± 0.1 0.5± 0.03 0.7± 0.1 0.9± 0.04 0.6± 0.1 0.6± 0.1 –
LDL Cholesterol (mmol/L) 0.2± 0.1 0.2± 0.08 0.1± 0.1 0.1± 0.1 0.2± 0.1 0.26± 0.1 –
Notes.
Data are expressed as the mean± SD of three rabbits per group.
proteins (e.g., osteopontin and collagen type I) in bone defects treated with the bioconstruct
(Arrigoni et al., 2013).
The current study showed significantly stronger expression of OPN in the OPG-chitosan
gel group compared to the control group, which supports the osteogenic potential of the
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OPG-chitosan gel. All groups showed higher expression of OPN at 6 weeks compared to 12
weeks, but no significant difference was observed for OC expression in the OPG-chitosan
gel group. This is in agreement with other studies that found that OPN is expressed
throughout matrix maturation, and OC seems to play a role in the early stages of bone
formation, showing positive expression at the area of bone formation at 6 weeks (Al-Ghani,
Al-Hijazi & AL-Zubaydi, 2011; Kim et al., 2015).
In this study, OC expression was associated with mature bone, confirming its expression
as a late marker of osteogenesis. Osteocalcin is commonly localised adjacent to osteoblasts,
osteoid, and within osteocyte lacunae. Tera et al. (2014) observed OC staining in bone
defects in a rat model, and concluded that the staining was relatively weaker in the
regenerating bone compared to mature bone. The expression of OC in OPG-chitosan,
chitosan, and control groups was higher at 6 weeks compared to 12 weeks, except for OC
expression in the OPG-chitosan gel group, for which there was no significant difference.
Osteocalcin appears to play a role in the early stages of bone formation, and showed positive
expression at the area of bone formation at 6 weeks. The OC expression level was directly
related to the bone formation activity.
The results of this study confirm the important roles of OC and OPN in bone healing,
consistent with a study by Bondarenko et al. (2014). Evaluation of the biocompatibility
and osteoconductivity of the OPG-chitosan gel demonstrated the superiority of this gel in
terms of biocompatibility (no adverse reactions were observed), osteoconductivity, and
progressive osteogenesis during the entire bone-healing period. Complete wound closure
of the critical-sized bone defect filled with OPG-chitosan gel compared to chitosan gel and
the unfilled control further supports the favourable biological properties of this biomaterial
in a clinical situation. The immunohistological investigations presented here are consistent
with enhanced new bone formation in the OPG-chitosan group, as we observed increased
expression of OPN and OC when compared to the chitosan gel group and the untreated
control group. This can be explained by the characteristics of the OPG-chitosan gel,
which allows prolonged retention of OPG at the defect site. We demonstrated that OPG
is released from the OPG-chitosan gel in vivo, and it is possible that the controlled release
of OPG at the defect site enhances the recruitment of active osteoblasts and suppresses the
recruitment of osteoclasts, thereby improving bone regeneration. We previously reported
that the OPG-chitosan gel increases the in vitro proliferation of normal human osteoblasts
(Jayash et al., 2017a).
Cathepsin K is expressed by osteoclasts and osteoclast precursors, but is absent in
osteoblasts and osteocytes. Therefore, its expression is specific to the resorption phase of
bone metabolism (Drake et al., 1996). Osteoblasts control the formation and activity of
osteoclasts, as well as the resorption of bone through coupling mechanisms such as RANK,
RANKL, and OPG (Jeon et al., 2016; Pederson et al., 2008; Teti, 2013).
The cathepsin K immunohistochemical staining showed fewer osteoclasts in the defect
treated with OPG-chitosan gel than in the chitosan gel and control groups. This may
be due to the action of OPG, which acts as a decoy receptor for RANKL, blocking the
activation and maturation of osteoclasts. This observation is in agreement with previous
studies in which chitosan has been demonstrated to enhance bone growth in critical-size
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defects in rat, rabbit, and sheep models (Muzzarelli et al., 1994; Pang et al., 2005; Wang et
al., 2002). Previous studies have also shown a significant increase in bone formation in the
osseous healing area of rats, rabbits, dogs, and humans where the OPG or chitosan-based
biomaterial was applied (Ezoddini-Ardakani, 2011; Florczyk et al., 2013; Jung et al., 2014;
Lamoureux et al., 2007; Yao et al., 2011). Furthermore, the serum levels of markers of liver
and kidney function indicated no signs of any harmful systemic effects of treatment. This
is in agreement with a previous study that reported no adverse effects in the liver and
kidney resulting from administration of a chitosan drug for treating bone fractures (Ho et
al., 2015).
CONCLUSION
We conclude that the bioresorbable OPG-chitosan material induced the formation of
a significant quantity of bone in a critical-sized parietal bone defect in a rabbit model.
Although the chitosan gel group also yielded a greater amount of bone compared to the
control group at all time points, the amount of bone generated was significantly lower than
the OPG-chitosan gel at both 6 and 12 weeks. This study also reports that the OPG-chitosan
gel showed the best behaviour, both clinically and histologically. It is biocompatible when
used in vivo, and showed no adverse reactions. The combination of OPG and chitosan in
a gel resulted in significantly enhanced new bone formation compared to chitosan alone
or the untreated control in a rabbit model. This suggests that the enhanced new bone
formation can be attributed to local release of OPG. The OPG-chitosan gel has many
characteristics that make it suitable for bone repair and regeneration, highlighting its
potential benefits for tissue engineering applications.
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